About us
Who We Are
Delta4, founded in 2019, is an AI Drug Discovery TechBio company at the forefront of detecting relationships between drugs with a known safety profile and rare diseases. This allows us to unearth new indications that could potentially revolutionize the way treatments find their way to patients. With a dedicated team of professionals, ranging from computational biologists to intellectual property experts, Delta4 is driven by the singular mission of enhancing patient care across the globe.
Fast Facts:
- Year Established: 2019
- Headquarters: Alser Str. 23/Top 30, 1080 Wien, Austria
- Number of Employees: <20
- Key Solutions: Drug discovery and indication expansion leveraging Hyper-C, our AI-powered platform
Our work
What We Do
Discovering The Unseen
By harnessing the power of our unique AI-powered platform, Hyper-C, Delta4 has been at the spearhead of drug repurposing and indication expansion. Our main goal is to pinpoint undetected correlations between existing drugs and diseases. Through this, we present new therapeutic options more swiftly, economically, and efficiently than ever before.
Hyper-C: Our Pride
Operated by our highly skilled team of computational biologists, Hyper-C is our keystone in identifying these relationships. It’s not just about speed but the precision and accuracy with which we offer unique insights for drug repurposing and indication expansion.
Drug repurposing and indication expansion represent a paradigm shift, offering a cost-effective way to discover new uses for existing drugs. Our investment in Hyper-C is a testament to our commitment to revolutionizing the drug discovery space.
Our Team: The Heart of Delta4
Executive Leadership:
Kurt Herpel - CEO
Kurt Herpel (CEO) is a pharma executive with vast experience in leading organizations. Besides big pharma, he is experienced in start-up situations and smaller enterprises.
Klaus Kratochwill - CSO
Klaus Kratochwill (CSO) is a translational researcher, and biochemist by training. He is an expert in omics data generation and analysis. In Delta4, he is responsible for coordinating all scientific activities.
Alfred Steininger - CFO
Alfred Steininger (CFO) is a financial professional with a deep knowledge of banking and capital markets. He has worked in a couple of different countries and for both large and small organizations.
About us
Who We Are
At the core, Delta4 is more than just a company; it’s a collective of individuals passionate about finding better treatments for complex and rare diseases. Our team comprises computational biologists, medical and pharmaceutical experts, molecular biologists, full-stack developers, and intellectual property experts. The unifying force among us is the drive to aid patients worldwide. We’re not just here for innovation; we’re here to make a tangible difference.
Learn more about the vibrant and brilliant minds powering Delta4
Media Assets
Delta4 Team
Logos
Recent Press Releases
Delta4 Announces Prof. Doron Lancet To Join Scientific Advisory Board
VIENNA, Austria, March 6th, 2023 — Delta4, a digital drug discovery company focusing on the identification of new indications for …
Delta4 joins the EU-funded COST action PerMediK (Personalized medicine in chronic kidney disease: improved outcome based on Big Data)
The scientific aim of PerMediK is to support the development of a path towards personalized medicine in chronic kidney disease …
4P-Pharma And Delta4 Join Forces To Find And Develop Treatments For A Rare Autoimmune Chronic Liver Disease
Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical-stage biotechnology company, and Delta4, an Austrian digital …
Delta4, in preparation for the first clinical study, focused on FSGS
Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological, and …
Delta4 Announces Dr. Hans Lehrach to Join Scientific Advisory Board
VIENNA, Austria, September 27th, 2021 — Delta4, a digital drug discovery company focusing on the identification of new indications for …
Press Release – April ’21
Delta4 Announces Closing of Multi-million Series A Financing Round Company to Expand Focus Beyond Renal Diseases and COVID-19 Compounds Identified …
Press Release – June 2020
Delta4 Announces Results Achieved with Drug Discovery Platform Vienna, Europe (June 2, 2020) – Delta4, a biotech company using its …
Contact Us
For media inquiries, partnership opportunities, or more information:
- Media Relations Contact: Dorota Wojenska
- Email: office@delta4.ai
- Phone: +43 681 817 051 48
- LinkedIn: https://www.linkedin.com/company/delta4ai/
- Twitter: https://twitter.com/Delta4ai
Thank you for your interest in Delta4. We are driven by innovation and the ambition to pave a brighter path in healthcare, transforming lives worldwide.